Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH.sub.1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.